Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial

Journal of Pharmacology and Pharmacotherapeutics

Volumn 4, Issue 1, 2013, Pages 27-32

  Chawla, Shalini ^a   Kaushik, Nitin ^a   Singh, Narinder Pal ^b   Ghosh, Raktim Kumar ^a   Saxena, Alpana ^b  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b LOK NAYAK HOSPITAL   (India)

Author keywords

add on therapy; diabetes mellitus; DPP 4 inhibitors

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WEIGHT CHANGE;

EID: 84875710868     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.107656     Document Type: Article

References (26)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. (Pubitemid 38579764)
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12. (Pubitemid 29254858)
3. Deeks ED, Scott LJ. Pioglitazone/metformin. Drugs 2006;66:1863-77. (Pubitemid 44584007)
4. Mohan V, Joshi SR. The Rosiglitazone Controversy: The Indian Perspective. J Assoc Physicians India 2007;55:477-80.
5. Gallwitz B. Review of sitagliptin phosphate: A novel treatment for type 2 diabetes. Vasc Health Risk Manag 2007;3:203-10. (Pubitemid 46860709)
6. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med 1990;7:445-51. (Pubitemid 20183935)
7. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res 2007;125:217-30. (Pubitemid 46805444)
8. Wulan SN, Westerterp KR, Plasqui G. Ethnic differences in body composition and the associated metabolic profile: A comparative study between Asians and Caucasians. Maturitas 2010;65:315-9.
9. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Sitagliptin study 020 group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43. (Pubitemid 44912191)
10. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Sitagliptin study 035 group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45. (Pubitemid 47261855)
11. Scott R, Loeys T, Davies MJ, Engel SS. Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-69.
12. Ludvik B, Daniela L. Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. Wien Klin Wochenschr 2011;123:235-40.
13. Reasner C, Olansky L, Seck TL, Williams-Herman DE, Chen M, Terranella L, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:644-52.
14. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-409. (Pubitemid 32056079)
15. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: A 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82-90. (Pubitemid 350302434)
16. Matthews DR, Charbonnel BH, Hanefeld M. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: A randomized, comparative study. Diabetes Metab Res Rev 2005;21:167-74. (Pubitemid 40467663)
17. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24:537-50. (Pubitemid 351294402)
18. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Sitagliptin study 024 group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205. (Pubitemid 46206563)
19. Bourdel-Marchasson I, Schweizer A, Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract (Minneap) 2011;39:7-21.
20. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:366-73.
21. Berhanu P, Kipnes MS, Khan MA, Perez AT, Kupfer SF, Spanheimer RG, et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res 2006;3:39-44. (Pubitemid 43877252)
22. Pfützner A, Schöndorf T, Tschöpe D, Lobmann R, Merke J, Müller J, et al. PIOfix-Study: Effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther 2011;13:637-43.
23. Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: Results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf 2009;32:787-800.
24. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: Similarities and differences. Drugs 2011;71:1441-67.
25. Sitagliptin (marketed as Januvia and Janumet)-acute pancreatitis FDA safety information. [0nline]. 2009 September 25; Available from: URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm183800.htm [Last cited on 2010 Jan 07].
26. Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobinA1c above target on metformin monotherapy. Diabetes Obes Metab 2008;10:43-55.